$Venetoclax durable response in adult relapsed/refractory Philadelphia-negative acute lymphoblastic leukemia with JAK/STAT pathway alterations$

Venetoclax durable response in adult relapsed/refractory Philadelphia-negative acute lymphoblastic leukemia with JAK/STAT pathway alterations

High-risk relapsed/refractory adult Philadelphia-negative (Ph−) B-cell acute lymphoblastic leukemia (B-ALL) is a great challenge due to limited possibilities to achieve and maintain a complete response. This also applies to cases with extramedullary (EM) involvement that have poor outcomes and no ac...

Full description

Bibliographic Details
Main Authors:	Anna Ferrari, Delia Cangini, Andrea Ghelli Luserna di Rorà, Annalisa Condorelli, Marta Pugliese, Giovanni Schininà, Sebastiano Cosentino, Eugenio Fonzi, Chiara Domizio, Giorgia Simonetti, Salvatore Leotta, Giuseppe Milone, Giovanni Martinelli
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-05-01
Series:	Frontiers in Cell and Developmental Biology
Subjects:	acute lymphoblastic leukemia venetoclax (BCL-2 inhibitor) Philadelphia-negative cells JAK/STAT extramedullary
Online Access:	https://www.frontiersin.org/articles/10.3389/fcell.2023.1165308/full

Similar Items

The balance between mitotic death and mitotic slippage in acute leukemia: a new therapeutic window?
by: Andrea Ghelli Luserna di Rorà, et al.
Published: (2019-11-01)

Real-world experience with venetoclax-based therapy for patients with myeloid sarcoma
by: Xinyi Jian, et al.
Published: (2024-06-01)

Targeting Proliferation Signals and the Cell Cycle Machinery in Acute Leukemias: Novel Molecules on the Horizon
by: Andrea Ghelli Luserna di Rorà, et al.
Published: (2023-01-01)

A WEE1 family business: regulation of mitosis, cancer progression, and therapeutic target
by: Andrea Ghelli Luserna di Rorà, et al.
Published: (2020-09-01)

Flumatinib plus venetoclax as an effective therapy for Philadelphia chromosome‐positive acute myeloid leukemia: A case report
by: Si‐Man Huang, et al.
Published: (2023-01-01)

Combination of venetoclax with BCR-ABL tyrosine kinase inhibitor as a therapeutic strategy for Philadelphia chromosome-positive leukemias
by: Jing-Ying Zou, et al.
Published: (2023-12-01)

Targeting PARP proteins in acute leukemia: DNA damage response inhibition and therapeutic strategies
by: Antonella Padella, et al.
Published: (2022-01-01)

The expanding role of venetoclax in chronic lymphocytic leukemia and small lymphocytic lymphoma
by: Schieber M, et al.
Published: (2019-03-01)

CDC20 in and out of mitosis: a prognostic factor and therapeutic target in hematological malignancies
by: Samantha Bruno, et al.
Published: (2022-04-01)

Development of venetoclax for therapy of lymphoid malignancies
by: Zhu H, et al.
Published: (2017-03-01)

B-cell lymphoma 2 inhibitor venetoclax treatment of a patient with cutaneous T-cell lymphoma
by: Amber Loren O. King, BA, et al.
Published: (2021-02-01)

Hematologic Tumor Cell Resistance to the BCL-2 Inhibitor Venetoclax: A Product of Its Microenvironment?
by: Joel D. Leverson, et al.
Published: (2018-10-01)

AML with BCR-ABL1 Fusion treated with Imatinib, a Hypomethylating Agent and Venetoclax
by: Soon Khai Low, et al.
Published: (2022-01-01)

Venetoclax-Related Neutropenia in Leukemic Patients: A Comprehensive Review of the Underlying Causes, Risk Factors, and Management
by: Laura Giuseppina Di Pasqua, et al.
Published: (2024-04-01)

Mechanisms of venetoclax resistance and solutions
by: Jiachen Liu, et al.
Published: (2022-10-01)

A novel Mcl-1 inhibitor synergizes with venetoclax to induce apoptosis in cancer cells
by: Tianming Zhao, et al.
Published: (2023-01-01)

Venetoclax Overcomes Sorafenib Resistance in Acute Myeloid Leukemia by Targeting BCL2
by: Xi Xu, et al.
Published: (2023-10-01)

Philadelphia : the unexpected city /
by: 384484 Lafore, Laurence Davis, et al.
Published: (1965)

Population Pharmacokinetic Models of Venetoclax in Hematologic Malignancies: A Systematic Review
by: Zhao Y, et al.
Published: (2024-05-01)

Clinical experiences with venetoclax and other pro-apoptotic agents in lymphoid malignancies: lessons from monotherapy and chemotherapy combination
by: Thomas E. Lew, et al.
Published: (2022-06-01)

Partial response to venetoclax and ruxolitinib combination in a case of refractory T-prolymphocytic leukemia
by: Joel Brothers, et al.
Published: (2023-12-01)

Man-made Philadelphia : a guide to its physical and cultural environment /
by: 218330 Wurman, Richard Saul, et al.
Published: (1972)

Venetoclax in relapsed/refractory blastic plasmacytoid dendritic cell neoplasm with central nervous system involvement: a case report and review of the literature
by: Nil Albiol, et al.
Published: (2021-06-01)

CS2164 and Venetoclax Show Synergistic Antitumoral Activities in High Grade B-Cell Lymphomas With MYC and BCL2 Rearrangements
by: Delin Yuan, et al.
Published: (2021-03-01)

225Ac‐labeled CD33‐targeting antibody reverses resistance to Bcl‐2 inhibitor venetoclax in acute myeloid leukemia models
by: Ravendra Garg, et al.
Published: (2021-02-01)

Synthesis of Novel Tryptamine Derivatives and Their Biological Activity as Antitumor Agents
by: Giorgia Simonetti, et al.
Published: (2021-01-01)

CMV Colitis: A Rare Complication of Azacitidine and Venetoclax Chemotherapy
by: Mustafa Nissar Bankur, et al.
Published: (2022-06-01)

Bcl-2 inhibition in the treatment of hematologic malignancies
by: John X. Wei, et al.
Published: (2023-12-01)

Investigating resistance to 5-Azacytidine and Venetoclax in PDX models of MDS/AML
by: Petra Bašová, et al.
Published: (2025-01-01)

Case Report: Contrasting BCL2 Upregulation With Venetoclax in a Case of Refractory Lymphomatoid Papulosis and Progressive Chronic Lymphocytic Leukemia
by: Valerio Guarente, et al.
Published: (2021-09-01)

VENETOCLAX IN TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (literature review)
by: T. E. Byalik
Published: (2018-07-01)

Venetoclax: evidence to date and clinical potential
by: Luis Miguel Juárez-Salcedo, et al.
Published: (2019-10-01)

Efficacy and Safety of Bcl-2 Inhibitor Venetoclax in Hematological Malignancy: A Systematic Review and Meta-Analysis of Clinical Trials
by: Qingfang Li, et al.
Published: (2019-06-01)

Preclinical evaluation of combination nemtabrutinib and venetoclax in chronic lymphocytic leukemia
by: Elizabeth M. Muhowski, et al.
Published: (2022-11-01)

Case report: An intriguing case of Philadelphia chromosome–positive acute lymphoblastic leukemia recurrence
by: Nicolò Peccatori, et al.
Published: (2024-07-01)

The venetoclax/azacitidine combination targets the disease clone in Acute Myeloid Leukemia, being effective and safe in a patient with COVID
by: Antonio Cristiano, et al.
Published: (2022-04-01)

Tumor Lysis Syndrome with Venetoclax/Carfilzomib/Dexamethasone for Relapsed/Refractory Multiple Myeloma: A Case Report
by: Reilly Fankhauser, et al.
Published: (2024-11-01)

Venetoclax resistance induced by activated T cells can be counteracted by sphingosine kinase inhibitors in chronic lymphocytic leukemia
by: Valeria J. Sarapura Martinez, et al.
Published: (2023-03-01)

High <i>BECN1</i> Expression Negatively Correlates with <i>BCL2</i> Expression and Predicts Better Prognosis in Diffuse Large B-Cell Lymphoma: Role of Autophagy
by: Amreen Salwa, et al.
Published: (2023-07-01)

Venetoclax in the treatment of secondary plasma cell leukemia with translocation t(11;14): a case report and literature review
by: Hesham Elsabah, et al.
Published: (2024-07-01)